OncoMatch/Clinical Trials/NCT07309185
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
Is NCT07309185 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Irinotecan for stomach neoplasms.
Treatment: Adebrelimab · Irinotecan · Malic acid Famitinib — This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent/metastatic gastric cancer,
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Gastric Cancer
Disease stage
Metastatic disease required
advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; at least one measurable lesion that has not received local treatment such as radiotherapy (RECIST v1.1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic chemotherapy — first-line
previously failed first-line treatment including systemic chemotherapy
Must have received: checkpoint inhibitor — first-line
previously failed first-line treatment including...immune checkpoint inhibitors, and have maintained first-line use of immune checkpoint inhibitors for at least 3 months
Cannot have received: paclitaxel (paclitaxel)
Patients who have received previous treatment with paclitaxel drugs
Cannot have received: anti-tumor therapy
Exception: within 2 weeks prior to the first use of the investigational drug
Received anti-tumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization) within 2 weeks prior to the first use of the investigational drug
Cannot have received: investigational drug
Exception: within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug
Received any other investigational drug within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug
Cannot have received: anti-tumor vaccine
Exception: within 4 weeks prior to the first administration of the study drug
Individuals who have received anti-tumor vaccines or have received live vaccines within 4 weeks prior to the first administration of the study drug
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L
Kidney function
CrCl ≥ 60 ml/min/1.73 m2 (Cockcroft Gault formula)
Liver function
serum total bilirubin ≤ 1.5x ULN, AST and ALT ≤ 2.5x ULN (≤ 5x ULN if liver metastasis)
The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 10^9/L (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml/min/1.73 m2 (calculated according to the Cockcroft Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07309185 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior paclitaxel, anti-tumor therapy, investigational drug disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages